Details for New Drug Application (NDA): 204171
✉ Email this page to a colleague
NDA 204171 describes ARIPIPRAZOLE, which is a drug marketed by Amneal Pharms, Apotex, Aurobindo Pharma Ltd, Chartwell Rx, Hetero Labs Ltd Iii, Lannett Co Inc, Rubicon, Vistapharm, Alembic, Orbion Pharms, Sciegen Pharms Inc, Square Pharms, Accord Hlthcare, Ajanta Pharma Ltd, Alkem Labs Ltd, Aurobindo Pharma, Breckenridge, Hetero Labs Ltd V, Lupin, Macleods Pharms Ltd, Norvium Bioscience, Prinston Inc, Sunshine, Teva Pharms Usa, Torrent, Unichem, and Zydus Pharms, and is included in thirty-four NDAs. It is available from forty-seven suppliers. Additional details are available on the ARIPIPRAZOLE profile page.
The generic ingredient in ARIPIPRAZOLE is aripiprazole. There are forty-nine drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.
The generic ingredient in ARIPIPRAZOLE is aripiprazole. There are forty-nine drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.
Summary for 204171
| Tradename: | ARIPIPRAZOLE |
| Applicant: | Lannett Co Inc |
| Ingredient: | aripiprazole |
| Patents: | 0 |
Suppliers and Packaging for NDA: 204171
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ARIPIPRAZOLE | aripiprazole | SOLUTION;ORAL | 204171 | ANDA | ATLANTIC BIOLOGICALS CORP. | 17856-0570 | 17856-0570-1 | 72 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE (17856-0570-1) / 5 mL in 1 CUP, UNIT-DOSE |
| ARIPIPRAZOLE | aripiprazole | SOLUTION;ORAL | 204171 | ANDA | ATLANTIC BIOLOGICALS CORP. | 17856-0570 | 17856-0570-2 | 48 SYRINGE in 1 BOX, UNIT-DOSE (17856-0570-2) / 5 mL in 1 SYRINGE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 1MG/ML | ||||
| Approval Date: | Aug 14, 2015 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
